Erdafitinib is developed and produced by which foreign company?

Erdafitinib (Erdafitinib) is developed and produced by the world's leading biopharmaceutical company - the American company Irish Pharmaceuticals (Janssen Pharmaceuticals), whose parent company is Johnson & Johnson (Johnson & Johnson). The development of this drug marks a significant breakthrough for scientists in the treatment of malignant tumors such as urothelial cancer.

Irish Pharmaceuticals, one of the pharmaceutical divisions of Johnson & Johnson, is committed to developing innovative biomedical technologies and pharmaceutical products to meet the needs of patients around the world for efficient and safe treatments. As a company with strong R&D capabilities and rich pharmaceutical experience globally, Irish Pharmaceuticals has always been at the forefront of cancer research.

The successful development of erdafitinib benefits from an in-depth understanding of the molecular mechanisms of cancer and continuous innovation in targeted therapies. The drug is unique in its targeted inhibition of FGFR (fibroblast growth factor receptor), which offers a new therapeutic avenue for treating certain types of cancer, such as urothelial cancer.

As one of the giants in the global pharmaceutical industry, Johnson & Johnson has not only achieved great success in drug research and development, but is also committed to promoting innovation in medical technology to improve the quality of life of patients around the world. The advent of erdafitinib provides a new treatment option for patients with advanced urothelial cancer, demonstrates the results of the joint efforts of scientists and pharmaceutical companies, and brings new hope to cancer patients.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.